105 related articles for article (PubMed ID: 23888693)
1. Structure-based identification of drug-like inhibitors of p300 histone acetyltransferase.
Zeng FQ; Peng SM; Li L; Mu LB; Zhang ZH; Zhang ZY; Huang N
Yao Xue Xue Bao; 2013 May; 48(5):700-8. PubMed ID: 23888693
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
6. Azide-alkyne cycloaddition affording enzymatically tunable bisubstrate based inhibitors of histone acetyltransferase PCAF.
van Ameijde J; Zwiebel AP; Ruijtenbeek R; Liskamp RM
Bioorg Med Chem Lett; 2014 Jan; 24(1):113-6. PubMed ID: 24345448
[TBL] [Abstract][Full Text] [Related]
7. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
8. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
Sagar V; Zheng W; Thompson PR; Cole PA
Bioorg Med Chem; 2004 Jun; 12(12):3383-90. PubMed ID: 15158807
[TBL] [Abstract][Full Text] [Related]
9. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
[TBL] [Abstract][Full Text] [Related]
10. Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs.
Karukurichi KR; Cole PA
Bioorg Chem; 2011 Feb; 39(1):42-7. PubMed ID: 21111442
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
12. Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.
Dancy BM; Crump NT; Peterson DJ; Mukherjee C; Bowers EM; Ahn YH; Yoshida M; Zhang J; Mahadevan LC; Meyers DJ; Boeke JD; Cole PA
Chembiochem; 2012 Sep; 13(14):2113-21. PubMed ID: 22961914
[TBL] [Abstract][Full Text] [Related]
13. Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF.
Wisastra R; Ghizzoni M; Maarsingh H; Minnaard AJ; Haisma HJ; Dekker FJ
Org Biomol Chem; 2011 Mar; 9(6):1817-22. PubMed ID: 21267493
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
Ravindra KC; Selvi BR; Arif M; Reddy BA; Thanuja GR; Agrawal S; Pradhan SK; Nagashayana N; Dasgupta D; Kundu TK
J Biol Chem; 2009 Sep; 284(36):24453-64. PubMed ID: 19570987
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities.
Souto JA; Conte M; Alvarez R; Nebbioso A; Carafa V; Altucci L; de Lera AR
ChemMedChem; 2008 Sep; 3(9):1435-42. PubMed ID: 18537201
[TBL] [Abstract][Full Text] [Related]
17. Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues.
Maksimoska J; Segura-Peña D; Cole PA; Marmorstein R
Biochemistry; 2014 Jun; 53(21):3415-22. PubMed ID: 24819397
[TBL] [Abstract][Full Text] [Related]
18. Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase.
Ghizzoni M; Haisma HJ; Dekker FJ
Eur J Med Chem; 2009 Dec; 44(12):4855-61. PubMed ID: 19683843
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
Dai Q; Yuan Z; Sun Q; Ao Z; He B; Jiang Y
Bioorg Med Chem Lett; 2024 May; 104():129742. PubMed ID: 38604299
[TBL] [Abstract][Full Text] [Related]
20. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]